Potassium Chloride: Development, Replacement Therapy, Safety and Pharmacovigilance

A lifecycle and product-safety review of potassium chloride, distinguishing solid oral, liquid and intravenous presentations and the limits of public-label listedness.

Take test

Potassium Chloride: Development, Replacement Therapy, Safety and Pharmacovigilance

Potassium chloride is an essential electrolyte-replacement medicine, but its safety is inseparable from route, dose, release technology and renal function. A solid oral tablet may cause gastrointestinal injury; an intravenous concentrate administered incorrectly may cause fatal arrhythmia; and oral or intravenous excess may produce hyperkalaemia when excretion is impaired. Conversely, insufficient replacement can leave clinically important potassium depletion unresolved. The same active substance therefore presents distinct formulation-dependent safety problems. [1,2]

Discovery and pharmaceutical development

A mineral medicine without a single molecular inventor

Potassium chloride is an inorganic salt rather than a proprietary receptor-targeting drug. Its medicinal development followed the recognition of potassium as an essential intracellular electrolyte, advances in serum electrolyte measurement and the evolution of oral and parenteral fluid therapy. The sources reviewed do not establish a defensible single inventor or inaugural pivotal clinical trial. The February 2026 US tablet label gives 1948 as initial US approval for potassium chloride, but that date is not evidence that the currently marketed Rising Pharma extended-release formulation was approved in 1948. A salt-replacement medicine cannot be given the discovery-and-pivotal-trial chronology of a modern patented drug. [1]

The distinctive commercial and technical lifecycle is the evolution of presentations. Oral solutions disperse potassium through fluid; solid formulations improve portability and adherence but can create high local mucosal concentrations; microencapsulated and extended-release tablets aim to reduce that exposure without eliminating it. US product information still warns about gastrointestinal ulceration, stenosis, obstruction and perforation with solid oral potassium chloride. [1,2] Manufacturer-specific formulations and instructions therefore matter more to case interpretation than the chemical name alone.

Chemistry and dose-unit safety

Potassium chloride dissociates into potassium and chloride ions. Its dose is commonly expressed as milliequivalents (mEq) of potassium, while a package may additionally state milligrams of potassium chloride. For monovalent potassium, 1 mmol potassium equals 1 mEq; approximately 74.55 mg KCl supplies 1 mEq potassium. Thus 750 mg KCl is approximately 10 mEq and 1,500 mg approximately 20 mEq. This is not the same as 750 mg of elemental potassium. [1]

A case report stating "potassium 20" is insufficient for a reliable dose assessment. Preserve the package, strength, unit, salt, formulation, route, concentration and actual amount administered. A dietary salt substitute, tablet, oral solution and IV concentrate cannot be treated as interchangeable exposure records.

Pharmacology and rationale for replacement

Potassium is the principal intracellular cation and contributes to resting membrane potential, neuromuscular excitability and cardiac conduction. Renal excretion, distal tubular flow and aldosterone influence potassium balance. Deficiency may arise from diuretic treatment, gastrointestinal losses, insufficient intake or redistribution into cells. A serum potassium concentration does not directly measure total-body potassium deficit, and the deficit may persist after an initial laboratory correction.

Changing benefit-risk with kidney function

The same replacement dose may be reasonable while potassium loss continues and hazardous when that loss stops or acute kidney injury develops. Insulin, acid–base disturbances, renal function, ongoing diarrhoea and concomitant drugs may alter measured potassium independently of a new replacement dose. Follow-up therefore requires serial measurements, chronology and physiological context, not merely a before-and-after number.

Replacement is a dynamic treatment, not a fixed exposure

A potassium result is a measurement of extracellular concentration at a particular time, not a direct inventory of intracellular stores. Ongoing gastrointestinal or renal losses can coexist with an apparently corrected serum value, while abrupt renal deterioration can make a previously appropriate maintenance regimen excessive. This distinction explains why a suspected adverse reaction should be reconstructed as a time series: the indication and initial deficit, replacement administered, continuing losses, renal function, co-medications and subsequent biochemical and clinical response.

There are three different questions in a potassium safety assessment. Was replacement indicated? This requires the clinical reason for hypokalaemia and relevant contemporaneous tests. Was the prescribed presentation and administration appropriate? This requires product-specific instructions, units and route. Did an adverse clinical outcome occur because of the treatment? This requires event verification, competing explanations and a reasoned causal assessment. The first two may reveal a medication-use problem without proving that the product caused the outcome; conversely, a serious adverse reaction can occur despite correct prescribing.

The distinction is especially important for reports of apparent treatment failure. Persistent hypokalaemia after oral replacement can reflect continued diuretic or gastrointestinal loss, coexisting magnesium depletion, redistribution, nonadherence, inadequate delivered dose or a documentation error. Escalation without resolving the cause may increase risk if renal function or potassium losses subsequently change. The PV record should not translate every low laboratory value into an adverse drug reaction or automatically treat lack of effect as a serious ICSR.

Why the release formulation matters

Solid oral potassium products are not equivalent merely because the number of mEq is identical. A tablet's release mechanism and passage through the oesophagus and gastrointestinal tract influence local contact exposure, while renal physiology determines systemic potassium accumulation. A French prolonged-release product may use an insoluble matrix that is later observed in stool; the named KALEORID RCP explains this phenomenon in section 4.2. Such a report should not be assumed to show non-absorption or a product defect without examining the product instructions and clinical response. [6]

This creates two separate safety axes: local mucosal injury and systemic electrolyte toxicity. A patient can have gastrointestinal intolerance with normal potassium, or life-threatening hyperkalaemia without any GI symptoms. The mechanisms, differential diagnoses, follow-up and risk minimisation differ. A combined label table is useful for teaching, but case processing should not collapse the events into a single generic potassium-intolerance concept.

Evidence and indication boundaries

The identified US extended-release tablet label describes replacement and prophylaxis of hypokalaemia under defined circumstances, rather than general treatment of hypertension. [1] A 1997 meta-analysis of 33 trials suggested modest blood-pressure reduction with potassium supplementation, whereas a 2006 Cochrane review considered the smaller hypertension evidence base inconclusive. A 2013 systematic review found blood-pressure reductions with increased potassium intake, particularly among hypertensive adults. [3,4,5] These studies of dietary or supplemental potassium do not establish an indication for a specific prescription extended-release tablet as an antihypertensive, nor justify supplementation without consideration of renal excretion and baseline potassium.

Major safety concerns

Hyperkalaemia and impaired elimination

Hyperkalaemia is the central systemic hazard. Renal impairment, excessive replacement, interacting medicines and physiological changes can produce dangerous potassium accumulation. Severe hyperkalaemia may cause weakness, ECG abnormalities, arrhythmia or cardiac arrest, but can also be asymptomatic before an abrupt deterioration. The selected US label identifies hyperkalaemia among reported adverse reactions and addresses it in overdose precautions. [1]

For a suspected reaction, capture baseline and peak potassium values with times, sample haemolysis, renal function, urine output, ECG, total potassium sources, medication changes, actual administered dose and subsequent response. Do not assume that a haemolysed specimen proves true hyperkalaemia, or that a normal earlier result excludes a subsequent serious event. Clinical emergencies require immediate treatment according to local protocols, not delayed pharmacovigilance adjudication.

Gastrointestinal injury from solid oral products

The most distinctive formulation hazard is local contact injury. US product information describes ulcerative or stenotic lesions, particularly where a solid dosage form remains against gastrointestinal mucosa. The label advises considering liquid potassium in patients with swallowing disorders, dysphagia or severe gastrointestinal motility disorders and warns about severe abdominal pain, distension, bleeding and vomiting. [1,2]

Nausea, vomiting, flatulence, abdominal discomfort and diarrhoea are also listed for oral potassium salts. These common symptoms are not synonymous with obstruction, ulceration or perforation. A meaningful case record distinguishes symptom from confirmed diagnosis, documents the exact formulation, whether the tablet lodged or was crushed, and relevant endoscopy or imaging.

Interactions and acute changes in renal physiology

The named US extended-release tablet label contraindicates concomitant triamterene or amiloride. It calls for monitoring with renin–angiotensin–aldosterone system inhibitors and NSAIDs because these can increase hyperkalaemia risk. [1] These are statements from a specific US product label; they are not automatically universal contraindications for every potassium formulation or jurisdiction.

An ACE inhibitor, angiotensin-receptor blocker, mineralocorticoid receptor antagonist, potassium-sparing diuretic, NSAID or potassium-containing salt substitute may alter the assessment. A previously tolerated combination can become hazardous after dehydration or acute kidney injury. A causal narrative should record when physiology changed as well as when each medicine was started.

Intravenous concentration and administration errors

Intravenous potassium chloride has a different risk profile from oral tablets. Inadvertent rapid or undiluted administration of concentrated potassium chloride can cause abrupt hyperkalaemia and fatal arrhythmia. The oral-tablet label reviewed here is not an intravenous prescribing reference. The exact injectable product information and institutional safeguards must govern IV practice.

An IV-related safety investigation should retain original orders, concentration, dilution, final bag volume, pump programming, administration rate, route, line, dispensing and preparation records, laboratory sequence and ECG. Distinguish prescribing, preparation and administration errors from product defects. If a quality complaint coexists, preserve linked but separate quality and safety investigations.

Product-specific listedness and limitations

US extended-release tablet source

The verified US comparator is DailyMed potassium chloride extended-release tablets, set ID 947c11ca-ca0c-42df-8cc5-3db06458ca5b, with 600-mg (8-mEq) and 750-mg (10-mEq) strengths, an SPL section date of 1 February 2026, accessed 10 November 2026. [1] This is a named solid oral product, not an umbrella USPI for all oral or IV potassium chloride products.

Safety concept Source location in named US label Interpretation
Nausea, vomiting, flatulence, abdominal discomfort, diarrhoea Section 6 Reported oral-salt adverse reactions; no reliable numerical frequency estimate
Hyperkalaemia Section 6; overdose Reported systemic risk; examine renal function and all sources
GI obstruction, bleeding, ulceration, perforation Sections 5.1 and 6 Serious documented GI hazards
Triamterene or amiloride Sections 4 and 7.1 Concomitant use contraindicated for this product
RAAS inhibitors and NSAIDs Sections 7.2–7.3 Interaction precautions, not proof of causality in a particular case

French prolonged-release tablet comparator and exact listedness

France: The ANSM public medicines database provides the RCP for KALEORID LP 1000 mg, comprimé à libération prolongée, an oral prolonged-release film-coated potassium chloride tablet containing 1,000 mg KCl (approximately 13.4 mmol potassium). The RCP displays 2 December 2020 as its text update date; accessed 11 November 2026. This is a nationally authorised French medicinal product, not an EMA centrally authorised product. The older revision date must be disclosed rather than silently represented as a 2026 label. The named product is distinct from the US 600/750-mg extended-release tablets. [6]

Section 4.8 of the French RCP lists the following preferred terms with frequency indeterminate (fréquence indéterminée, frequency not known): hyperkalaemia; intestinal or gastrointestinal perforation; gastrointestinal haemorrhage and haematemesis; gastric, duodenal and oesophageal ulcer; intestinal obstruction; gastrointestinal and oesophageal stenosis; diarrhoea, vomiting, abdominal pain and nausea. This is a term-level positive listedness determination for that French product at the specified revision. It does not imply that every adverse event associated with potassium chloride has been enumerated. [6]

Safety concept US Rising Pharma ER tablet, February 2026 French KALEORID LP 1000 mg, December 2020
Nausea, vomiting, diarrhoea, abdominal pain/discomfort Section 6 lists gastrointestinal adverse reactions, without a numerical frequency estimate Section 4.8 lists nausea, vomiting, diarrhoea and abdominal pain; frequency not known
Hyperkalaemia Section 6 and overdose information Section 4.8, frequency not known
Gastrointestinal ulceration, stenosis, obstruction, perforation or bleeding Sections 5.1 and 6 describe serious GI injury Section 4.8 explicitly lists several specific GI preferred terms, frequency not known
Potassium-sparing diuretics Triamterene and amiloride are contraindicated (sections 4, 7.1) Section 4.3 and 4.5 distinguish contraindicated combinations and circumstances involving documented hypokalaemia
ACE inhibitors, ARBs and NSAIDs RAAS inhibitors and NSAIDs are monitoring interactions in sections 7.2–7.3 Section 4.5 advises against ACE inhibitor/ARB combinations in specified circumstances and identifies NSAIDs among other hyperkalaemia-promoting medicines
Administration Swallow tablets whole with meals and fluid; do not crush, chew or suck Swallow whole with water; do not chew, bite or crush; product-specific matrix passage in stool described in section 4.2

The comparison highlights differences in the specificity and location of safety wording, not an established difference in biological risk or a head-to-head estimate of incidence. The French section 4.8 frequency category is not comparable to a trial incidence percentage, and the US contraindication for triamterene/amiloride must not be automatically extended to the entire French diuretic category without its contextual qualification. Neither the US nor the French oral tablet label is a source for injectable potassium chloride administration. [1,6]

A clinical report describing gastrointestinal bleeding after potassium replacement requires confirmation of the actual tablet, liquid or injectable presentation, source documentation, objective findings and concomitant medicines. For a formal expectedness assessment, apply the designated effective reference safety information for that product and jurisdiction; the above public-label comparison is not a substitute. Public-label listedness, company-core listedness, causality, seriousness and reportability are separate decisions.

Injectable formulation: a separate safety and regulatory pathway

A UK SmPC for Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion illustrates why parenteral potassium cannot be inferred from oral tablet information. Its section 4.8 reports postmarketing reactions with frequency not known, including infusion-site reactions and cardiac arrest as a possible manifestation of rapid IV administration and/or hyperkalaemia. The glucose-containing infusion has additional metabolic and hypersensitivity considerations that cannot be transferred to a plain potassium chloride concentrate. This UK document is included as a formulation-specific educational comparator, not as the EU member-state oral SmPC. [7]

An injectable report must distinguish ready-to-infuse solutions from concentrates requiring dilution and record concentration, dilution, route, rate, infusion device, line and laboratory chronology. Avoid universalising a product-specific infusion rate or concentration as a global rule; verify the actual authorised injectable label and local protocol. [7]

Practical pharmacovigilance

Case intake and follow-up

Capture indication, exact product, route, formulation, prescribed and actual dose, units, baseline electrolytes, renal function, concomitant medicines and serial clinical course. A valid safety case may contain both a medication error and an adverse reaction; neither should erase the other.

Reported problem Priority follow-up Alternative explanations
Hyperkalaemia Serial potassium, sample quality, renal function, ECG, all potassium sources Kidney injury, tissue breakdown, laboratory artefact
GI ulcer or obstruction Solid formulation, administration, swallowing history, imaging/endoscopy Existing GI disease, other ulcerogenic medicines
Persistent hypokalaemia Actual dose, continuing loss, magnesium, adherence Ongoing diuresis, diarrhoea, redistribution
IV-associated arrhythmia Concentration, pump record, rate, route, ECG and lab chronology Underlying cardiac disease, other electrolyte disturbances
Medication error Original order, preparation, dispensing and administration records Documentation or transcription errors

Illustrative interaction scenario

A hypothetical patient receiving potassium chloride for diuretic-associated hypokalaemia begins a potassium-retaining medicine. During an intercurrent illness renal function declines, and later potassium testing shows hyperkalaemia. Assessment should reconstruct medication reconciliation, monitoring, changing renal physiology and the total administered amount. The scenario illustrates multifactorial risk; it is not a real case report and does not establish which medicine caused the event.

Signal evaluation and prevention

Spontaneous reports cannot provide an incidence denominator. Separate oral from IV exposure, solid from liquid formulations, high-risk renal groups, concomitant medicines, medication errors and confirmed clinical outcomes. Review duplicates, case definitions and laboratory quality before interpreting a rise in reports. Disproportionality, if used, is a prioritisation tool rather than proof of causality.

Possible safeguards include explicit mEq units, standardised injectable concentrations, independent controls for concentrated injectables, medicine reconciliation, alerts for duplicate potassium sources and renal-function monitoring. These are risk-reduction practices, not necessarily statutory requirements in every jurisdiction. Evaluate effectiveness with actual error and harm outcomes, not only whether training occurred.

Governance and traceability

Maintain source records, medical review, coding decisions, reference safety information version, seriousness and expectedness reasoning, submission history and signal actions. Product quality and adverse-event systems should reconcile overlapping reports without conflating their investigations. Any proposed corrective action requires a responsible owner, documented implementation and evidence of effectiveness.

Key takeaways

Potassium chloride is not a uniform product risk. Route, dose units, release form, renal excretion, interactions and administration safeguards shape benefit and harm. The named US extended-release tablet label lists common gastrointestinal symptoms and serious hyperkalaemia and GI injury. The French KALEORID LP 1000 mg prolonged-release tablet RCP dated December 2020 also lists hyperkalaemia and specific gastrointestinal injuries with frequency not known. The two national oral labels differ in wording and formulation; no incidence comparison is justified.

References

  1. US National Library of Medicine. DailyMed. Potassium chloride extended-release tablets, set ID 947c11ca-ca0c-42df-8cc5-3db06458ca5b; SPL section date 1 February 2026. Sections 2–8 and 10. Accessed 10 November 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=947c11ca-ca0c-42df-8cc5-3db06458ca5b
  2. US National Library of Medicine. DailyMed. Mylan potassium chloride extended-release film-coated tablets, label revised September 2023; historical formulation comparator. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1af7e05-68ba-438e-a63b-cd8c23960c85
  3. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. JAMA. 1997;277:1624–1632. doi:10.1001/jama.1997.03540440058033. https://pubmed.ncbi.nlm.nih.gov/9168293/
  4. Dickinson HO, Nicolson D, Campbell F, et al. Potassium supplementation for primary hypertension. Cochrane Database Syst Rev. 2006;CD004641. doi:10.1002/14651858.CD004641.pub2. https://www.cochrane.org/evidence/CD004641_oral-potassium-supplementation-high-blood-pressure-adults
  5. Aburto NJ, Hanson S, Gutierrez H, et al. Increased potassium intake and cardiovascular risk factors. BMJ. 2013;346:f1378. https://pubmed.ncbi.nlm.nih.gov/23558164/
  6. Agence nationale de sécurité du médicament et des produits de santé (ANSM). KALEORID LP 1000 mg, comprimé à libération prolongée. Résumé des caractéristiques du produit, updated 2 December 2020; sections 4.2–4.8. Accessed 11 November 2026. https://m.base-donnees-publique.medicaments.gouv.fr/rcp-63382862-11
  7. UK electronic Medicines Compendium. Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion BP. Summary of Product Characteristics, sections 4.4 and 4.8. Accessed 11 November 2026. https://www.medicines.org.uk/emc/product/1859/smpc

Regulatory Note

This is an educational pharmacovigilance reference, not individual prescribing advice or an emergency-treatment protocol. Confirm the exact authorised product, route, strength, jurisdiction and current effective reference safety information before making clinical or regulatory decisions. An oral US label cannot be used as IV instructions; an unverified EU SmPC cannot establish listedness.

Revision History

QPPV.com